Breath Therapeutics, a Zambon company, initiates BOSTON-3 and BOSTON-4, two additional clinical studies for the treatment of bronchiolitis obliterans syndrome (BOS)
– Liposomal Cyclosporine A for Inhalation (L‑CsA‑i) is advancing in clinical studies for the treatment for bronchiolitis obliterans syndrome (BOS) – BOS is a devastating...